October 9, 2024
By: Michael Monostra In adults living with HIV, those with three or more metabolic risk factors had a higher risk for developing new-onset diabetes than those […]
October 9, 2024
Data from the REPRIEVE trial suggest there is only a minimal increased risk of diabetes with statins among people with HIV, and in specific, limited groups […]
October 8, 2024
Abstract Background: REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) led to new guidelines for statin use among people with HIV (PWH) with low to […]
October 7, 2024
Abstract Objectives: To determine baseline prevalence of proteinuria and albuminuria among REPRIEVE participants and evaluate associated risk factors. Design: Cross sectional analysis of a baseline sample of participants […]
September 11, 2024
Cardiovascular disease (CVD) rates are increased 50%-100% among people with HIV. The mechanisms of CVD in people with HIV include traditional risk factors such as smoking, […]
September 4, 2024
By John W. McEvoy and Cian Mangan The potential of high-sensitivity cardiac troponin (hs-cTn) assays to augment cardiovascular disease (CVD) prediction in primary prevention has long been an […]
August 28, 2024
Abstract Background: Little is known about the potential benefits or harms of statins on physical function among people with HIV (PWH). Methods: REPRIEVE was a double-blind randomized controlled […]
August 28, 2024
Abstract Background Coronary plaque is common among people with HIV (PWH) with low-to-moderate traditional atherosclerotic cardiovascular disease (ASCVD) risk. Objectives The purpose of this study was […]
July 29, 2024
People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of […]
October 9, 2024
By: Michael Monostra In adults living with HIV, those with three or more metabolic risk factors had a higher risk for developing new-onset diabetes than those […]
October 9, 2024
Data from the REPRIEVE trial suggest there is only a minimal increased risk of diabetes with statins among people with HIV, and in specific, limited groups […]
October 8, 2024
Abstract Background: REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) led to new guidelines for statin use among people with HIV (PWH) with low to […]
October 7, 2024
Abstract Objectives: To determine baseline prevalence of proteinuria and albuminuria among REPRIEVE participants and evaluate associated risk factors. Design: Cross sectional analysis of a baseline sample of participants […]
September 11, 2024
Cardiovascular disease (CVD) rates are increased 50%-100% among people with HIV. The mechanisms of CVD in people with HIV include traditional risk factors such as smoking, […]
September 4, 2024
By John W. McEvoy and Cian Mangan The potential of high-sensitivity cardiac troponin (hs-cTn) assays to augment cardiovascular disease (CVD) prediction in primary prevention has long been an […]
August 28, 2024
Abstract Background: Little is known about the potential benefits or harms of statins on physical function among people with HIV (PWH). Methods: REPRIEVE was a double-blind randomized controlled […]
August 28, 2024
Abstract Background Coronary plaque is common among people with HIV (PWH) with low-to-moderate traditional atherosclerotic cardiovascular disease (ASCVD) risk. Objectives The purpose of this study was […]
July 29, 2024
People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of […]